Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
PD-1 / PD-L1 antibodies block the programmed cell death protein 1 (PD-1) checkpoint on T cells or its ligand PD-L1. Binding of PD-L1 on tumor or antigen-presenting cells to PD-1 suppresses T-cell activation, so blocking either partner restores effector function in co-culture and tumor models. Anti-PD-1 antibodies in this group include pembrolizumab, nivolumab, cemiplimab, dostarlimab, tislelizumab and toripalimab. Atezolizumab, durvalumab and avelumab bind PD-L1 instead, and avelumab retains antibody-dependent cell-mediated cytotoxicity (ADCC). The antibodies serve as reference reagents in checkpoint blockade assays, receptor occupancy studies and combination experiments.
Synonyms: ATOR-1017
Evunzekibart (ATOR-1017) is a 4-1BB agonist that functions conditionally through Fc-γ receptor engagement, classified as an IgG4-type antibody. This biologic is designed to activate immune responses against cancer cells either as a standalone treatment or in synergy with anti-PD1 therapies, enhancing its potential for anticancer efficacy.
